Načítá se...
Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure
Three major cardiovascular outcome trials (CVOTs) with a new class of antidiabetic drugs - sodium-glucose cotransporter 2 (SGLT2) inhibitors (EMPA-REG OUTCOME trial with empagliflozin, CANVAS Program with canagliflozin, DECLARE-TIMI 58 with dapagliflozin) unexpectedly showed that cardiovascular outc...
Uloženo v:
| Vydáno v: | World J Diabetes |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7415232/ https://ncbi.nlm.nih.gov/pubmed/32843930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v11.i7.269 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|